Tocilizumab treatment in patients with rheumatoid arthritis results in better clinical outcomes,102,103 and other related studies have shown that serum IL6 levels and serum MIF (macrophage migration inhibitory factor [glycosylation-inhibiting factor]) levels are significantly decreased with tocilizumab treatment.104,105. This evidence concerns the gene IL6 and rheumatoid arthritis.